Annovis Bio (ANVS) announced it will begin an open-label extension study in January 2026 to evaluate the long-term safety and efficacy of buntanetap in PD patients.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
- Annovis Bio Receives Buy Rating Amid Promising Phase 3 Trial Results and Strategic FDA Discussions for Buntanetap
- Annovis announces FDA meeting to discuss PDD program
- Annovis Bio announces biomarker data on amyloid co-pathology in Parkinson’s
- Annovis Bio’s Strategic Advances and Insider Confidence Drive Buy Rating Amid Promising Alzheimer’s Treatment Progress